Bristol Will Not Ask FDA To Relist BuSpar Patent If Mylan Wins Patent Case
Executive Summary
Bristol-Myers Squibb will not ask FDA to relist its November 2000 BuSpar patent in the "Orange Book" if Mylan wins its challenge of the patent's validity in Manhattan federal court